

**DRAFT
TOXICOLOGICAL PROFILE FOR
ETHYLENE GLYCOL**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

September 2007

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

This information is distributed solely for the purpose of pre dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.

UPDATE STATEMENT

A Toxicological Profile for Ethylene Glycol and Propylene Glycol was released in 1997. This present edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine/Applied Toxicology Branch
1600 Clifton Road NE
Mailstop F-32
Atlanta, Georgia 30333

This page is intentionally blank.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. We plan to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Comments should be sent to:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine
1600 Clifton Road, N.E.
Mail Stop F-32
Atlanta, Georgia 30333


The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on December 7, 2005 (70 FR 72840). For prior versions of the list of substances, see *Federal Register* notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); February 28, 1994 (59 FR 9486); April 29, 1996 (61 FR 18744); November 17, 1997 (62 FR 61332); October 21, 1999 (64 FR 56792); October 25, 2001 (66 FR 54014); and November 7, 2003 (68 FR 63098). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Howard Frumkin, M.D., Dr. P.H.
Director

National Center for Environmental Health/
Agency for Toxic Substances and
Disease Registry



Julie Louise Gerberding, M.D., M.P.H.
Administrator

Agency for Toxic Substances and
Disease Registry

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Obaid Faroon, D.V.M., Ph.D.
Carolyn Tylenda, D.M.D., Ph.D.
Carolyn C. Harper, M.S., Ph.D.
Dianyi Yu, M.D., Ph.D.
Amanda Cadore, M.P.H.
ATSDR, Division of Toxicology and Environmental Medicine, Atlanta, GA

Stephen Bosch, B.S.
Daniel Plewak, B.S.
Heather Carlson-Lynch, S.M.
Syracuse Research Corporation, North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Applied Toxicology Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.

This page is intentionally blank.

PEER REVIEW

A peer review panel was assembled for ethylene glycol. The panel consisted of the following members:

1. Phillip Goad, Ph.D., Center for Toxicology and Environmental Health, LLC, North Little Rock, Arkansas;
2. Jerrold Leiken, M.D., ENH-OMEGA, Glenview, Illinois; and
3. Kenneth McMartin, Ph.D., Louisiana State University, Shreveport, Louisiana.

These experts collectively have knowledge of ethylene glycol's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

This page is intentionally blank.

CONTENTS

DISCLAIMER	ii
UPDATE STATEMENT	iii
FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS.....	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
CONTENTS.....	xiii
LIST OF FIGURES	xvii
LIST OF TABLES	xix
1. PUBLIC HEALTH STATEMENT.....	1
2. RELEVANCE TO PUBLIC HEALTH	9
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO ETHYLENE GLYCOL IN THE UNITED STATES.....	9
2.2 SUMMARY OF HEALTH EFFECTS.....	10
2.3 MINIMAL RISK LEVELS (MRLs)	16
3. HEALTH EFFECTS.....	35
3.1 INTRODUCTION.....	35
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	35
3.2.1 Inhalation Exposure	37
3.2.1.1 Death	37
3.2.1.2 Systemic Effects.....	37
3.2.1.3 Immunological and Lymphoreticular Effects.....	43
3.2.1.4 Neurological Effects.....	43
3.2.1.5 Reproductive Effects	44
3.2.1.6 Developmental Effects	45
3.2.1.7 Cancer.....	46
3.2.2 Oral Exposure.....	46
3.2.2.1 Death	47
3.2.2.2 Systemic Effects.....	48
3.2.2.3 Immunological and Lymphoreticular Effects.....	99
3.2.2.4 Neurological Effects.....	100
3.2.2.5 Reproductive Effects	103
3.2.2.6 Developmental Effects	105
3.2.2.7 Cancer.....	109
3.2.3 Dermal Exposure.....	110
3.2.3.1 Death	110
3.2.3.2 Systemic Effects.....	110
3.2.3.3 Immunological and Lymphoreticular Effects.....	112
3.2.3.4 Neurological Effects.....	112
3.2.3.5 Reproductive Effects	112
3.2.3.6 Developmental Effects	112
3.2.3.7 Cancer.....	113
3.3 GENOTOXICITY	113
3.4 TOXICOKINETICS	115
3.4.1 Absorption.....	115
3.4.1.1 Inhalation Exposure.....	115

3.4.1.2	Oral Exposure.....	116
3.4.1.3	Dermal Exposure.....	116
3.4.2	Distribution.....	117
3.4.2.1	Inhalation Exposure.....	117
3.4.2.2	Oral Exposure.....	117
3.4.2.3	Dermal Exposure.....	119
3.4.3	Metabolism.....	119
3.4.4	Elimination and Excretion.....	124
3.4.4.1	Inhalation Exposure.....	124
3.4.4.2	Oral Exposure.....	125
3.4.4.3	Dermal Exposure.....	127
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models.....	127
3.5	MECHANISMS OF ACTION.....	134
3.5.1	Pharmacokinetic Mechanisms.....	134
3.5.2	Mechanisms of Toxicity.....	135
3.5.3	Animal-to-Human Extrapolations.....	138
3.6	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS.....	139
3.7	CHILDREN'S SUSCEPTIBILITY.....	140
3.8	BIOMARKERS OF EXPOSURE AND EFFECT.....	144
3.8.1	Biomarkers Used to Identify or Quantify Exposure to Ethylene Glycol.....	145
3.8.2	Biomarkers Used to Characterize Effects Caused by Ethylene Glycol.....	147
3.9	INTERACTIONS WITH OTHER CHEMICALS.....	148
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE.....	149
3.11	METHODS FOR REDUCING TOXIC EFFECTS.....	149
3.11.1	Reducing Peak Absorption Following Exposure.....	150
3.11.2	Reducing Body Burden.....	151
3.11.3	Interfering with the Mechanism of Action for Toxic Effects.....	152
3.12	ADEQUACY OF THE DATABASE.....	152
3.12.1	Existing Information on Health Effects of Ethylene Glycol.....	153
3.12.2	Identification of Data Needs.....	155
3.12.3	Ongoing Studies.....	169
4.	CHEMICAL AND PHYSICAL INFORMATION.....	171
4.1	CHEMICAL IDENTITY.....	171
4.2	PHYSICAL AND CHEMICAL PROPERTIES.....	171
5.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL.....	175
5.1	PRODUCTION.....	175
5.2	IMPORT/EXPORT.....	179
5.3	USE.....	179
5.4	DISPOSAL.....	181
6.	POTENTIAL FOR HUMAN EXPOSURE.....	183
6.1	OVERVIEW.....	183
6.2	RELEASES TO THE ENVIRONMENT.....	183
6.2.1	Air.....	185
6.2.2	Water.....	185
6.2.3	Soil.....	188
6.3	ENVIRONMENTAL FATE.....	189
6.3.1	Transport and Partitioning.....	189
6.3.2	Transformation and Degradation.....	190

6.3.2.1	Air.....	190
6.3.2.2	Water	190
6.3.2.3	Sediment and Soil.....	191
6.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	192
6.4.1	Air	192
6.4.2	Water	193
6.4.3	Sediment and Soil	193
6.4.4	Other Environmental Media.....	193
6.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	194
6.6	EXPOSURES OF CHILDREN	195
6.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	197
6.8	ADEQUACY OF THE DATABASE.....	197
6.8.1	Identification of Data Needs	197
6.8.2	Ongoing Studies	201
7.	ANALYTICAL METHODS	203
7.1	BIOLOGICAL MATERIALS	203
7.2	ENVIRONMENTAL SAMPLES.....	208
7.3	ADEQUACY OF THE DATABASE.....	211
7.3.1	Identification of Data Needs	211
7.3.2	Ongoing Studies	212
8.	REGULATIONS AND ADVISORIES	213
9.	REFERENCES	217
10.	GLOSSARY	259
APPENDICES		
A.	ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
B.	USER'S GUIDE.....	B-1
C.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	C-1
D.	INDEX	D-1

This page is intentionally blank.

LIST OF FIGURES

3-1. Levels of Significant Exposure to Ethylene Glycol - Inhalation	39
3-2. Levels of Significant Exposure to Ethylene Glycol - Oral	79
3-3. Metabolic Pathway for Ethylene Glycol.....	121
3-4. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance.....	129
3-5. Existing Information on Health Effects of Ethylene Glycol.....	154
6-1. Frequency of NPL Sites with Ethylene Glycol Contamination.....	184

This page is intentionally blank.

LIST OF TABLES

3-1. Levels of Significant Exposure to Ethylene Glycol - Inhalation	38
3-2. Levels of Significant Exposure to Ethylene Glycol - Oral	49
3-3. Levels of Significant Exposure to Ethylene Glycol - Dermal	111
3-4. Genotoxicity of Ethylene Glycol <i>In Vitro</i>	114
3-5. Distribution of Radioactivity (Percent of Administered Dose) in Tissues 96 Hours After Oral or Percutaneous Exposure to ¹⁴ C-Ethylene Glycol.....	118
3-6. Radioactivity (Percent of Administered Dose) in Excreta 96 Hours After 6-Hour Occluded Percutaneous Exposure to ¹⁴ C-Ethylene Glycol.....	120
3-7. Radioactivity (Percent of Administered Dose) in Excreta 96 Hours After Oral or Exposure to ¹⁴ C-Ethylene Glycol	126
3-8. Physiological Parameters in PBPK Models for Ethylene Glycol	131
3-9. Biochemical Parameters in PBPK Models for Ethylene Glycol.....	132
4-1. Chemical Identity of Ethylene Glycol	172
4-2. Physical and Chemical Properties of Ethylene Glycol	173
5-1. Companies that Produce Ethylene Glycol in the United States and Annual Capacities During 2006.....	176
5-2. Facilities that Produce, Process, or Use Ethylene Glycol.....	177
5-3. U.S. Ethylene Glycol Imports and Exports by Year in Metric Tons	180
6-1. Releases to the Environment from Facilities that Produce, Process, or Use Ethylene Glycol	186
7-1. Analytical Methods for Determining Ethylene Glycol in Biological Materials	204
7-2. Analytical Methods for Determining Ethylene Glycol in Environmental Samples.....	209
8-1. Regulations and Guidelines Applicable to Ethylene Glycol	214